摘要 : Background: In October 2007, British Columbia started to cover the cost of cholinesterase inhibitors (ChEIs) donepezil, galantamine, and rivastigmine for patients with mild to moderate dementia and prominent Alzheimer's disease. O... 展开
作者 | Bassett~ Ken Chappell~ Neena L. Fisher~ Anat Carney~ Greg |
---|---|
作者单位 | |
期刊名称 | 《Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research》 |
总页数 | 9 |
语种/中图分类号 | 英语 / R1 |
关键词 | cholinesterase inhibitors dementia drug policy persistence |
馆藏号 | N2008EPST0005800 |